It is clear that the presence of infiltrating CD8+ T cells in combination with increased PD-L1 expression/amplification is positively associated with the therapeutic efficacy of PD-1 blockade, although patients with PD-L1-negative tumours might also respond to treatment.41 This evidence concerns the gene CD8A and neoplasm.